video-innovation-le-masque-reutilisable-a-l-infini-de-michelin

Les cookies nous permettent de vous proposer nos services plus facilement. En utilisant nos services, vous nous donnez expressément votre accord pour exploiter ces cookies.En savoir plus OK

Revenir à l'accueil

Voir également :

http://audentia-gestion.fr/actualite/0-SOMMAIRE-audentia-gestion.fr-actualite.htm

http://audentia-gestion.fr/actualite/5CarrefourOnline.htm

http://audentia-gestion.fr/actualite/600000-trinidadians-hypertension-diabetes-risk-covid-19.html

http://audentia-gestion.fr/actualite/Arnaud-Mercier-Burolab.html

http://audentia-gestion.fr/actualite/Arnaud-Mercier-Burolab1.html

http://audentia-gestion.fr/actualite/Boston-Globe-Events-Twitter.htm

http://audentia-gestion.fr/actualite/COVID-19-IMPACT-ON-OPTICAL-ACRYLIC-SHEET-MARKET.html

http://audentia-gestion.fr/actualite/Crepy.html

http://audentia-gestion.fr/actualite/Darmanin.html

http://audentia-gestion.fr/actualite/EBPenTelechargement.htm

http://audentia-gestion.fr/actualite/Etalab-Twitter.htm

http://audentia-gestion.fr/actualite/Expedia.html

http://audentia-gestion.fr/actualite/Gemo.html

http://audentia-gestion.fr/actualite/GroupeLaPoste-Twitter.htm

http://audentia-gestion.fr/actualite/Harbin.html

http://audentia-gestion.fr/actualite/Institut-Pasteur.html

http://audentia-gestion.fr/actualite/Kering.html

http://audentia-gestion.fr/actualite/Le-Souvenir-Francais-Twitter.htm

http://audentia-gestion.fr/actualite/Les-Francais-n-auront-surement-pas-le-droit-de-changer-de-region-apres-le-11-mai.html

http://audentia-gestion.fr/actualite/Les-offres-d-emploi-IT-devissent-de-40-pour-cent-en-un-mois.html

http://audentia-gestion.fr/actualite/Micropole.html

http://audentia-gestion.fr/actualite/Motorola-Edge.html

http://audentia-gestion.fr/actualite/NOUVELLES VERSIONS JANVIER 2013 Remise de 10.htm

http://audentia-gestion.fr/actualite/On-pourra-bientot-depenser-95-euros-en-tickets-restaurant.html

http://audentia-gestion.fr/actualite/Recherche-Google.htm

http://audentia-gestion.fr/actualite/Respirateurs.html

http://audentia-gestion.fr/actualite/SF_Siege-Twitter.htm

http://audentia-gestion.fr/actualite/TIME-magazine-lauds-role-of-Ghana-s-drones-in-coronavirus-fight.html

http://audentia-gestion.fr/actualite/Theradiag.html

http://audentia-gestion.fr/actualite/Toyota.html

http://audentia-gestion.fr/actualite/VIDEO-Confinement-avec-leur-parodie-de-Jacques-Brel.html

http://audentia-gestion.fr/actualite/Vallourec.html

http://audentia-gestion.fr/actualite/Videotron.html

http://audentia-gestion.fr/actualite/ViralClear-Publishes-Comparative-In-Vitro-Data-on-Merimepodib-and-Remdesivir-Activity-Against-the-COVID-19-Novel-Coronavirus-in-F1000-Research.htm

http://audentia-gestion.fr/actualite/actualite.htm

http://audentia-gestion.fr/actualite/actualite1.htm

http://audentia-gestion.fr/actualite/actualite10.htm

http://audentia-gestion.fr/actualite/actualite11.htm

http://audentia-gestion.fr/actualite/actualite12.htm

http://audentia-gestion.fr/actualite/actualite13.htm

http://audentia-gestion.fr/actualite/actualite14.htm

http://audentia-gestion.fr/actualite/actualite15.htm

http://audentia-gestion.fr/actualite/actualite16.htm

http://audentia-gestion.fr/actualite/actualite17.htm

http://audentia-gestion.fr/actualite/actualite18.htm

http://audentia-gestion.fr/actualite/actualite19.htm

http://audentia-gestion.fr/actualite/actualite2.htm

http://audentia-gestion.fr/actualite/actualite20.htm

http://audentia-gestion.fr/actualite/actualite21.htm

http://audentia-gestion.fr/actualite/actualite22.htm

http://audentia-gestion.fr/actualite/actualite23.htm

http://audentia-gestion.fr/actualite/actualite24.htm

http://audentia-gestion.fr/actualite/actualite25.htm

http://audentia-gestion.fr/actualite/actualite26.htm

http://audentia-gestion.fr/actualite/actualite27.htm

http://audentia-gestion.fr/actualite/actualite28.htm

http://audentia-gestion.fr/actualite/actualite29.htm

http://audentia-gestion.fr/actualite/actualite3.htm

http://audentia-gestion.fr/actualite/actualite30.htm

http://audentia-gestion.fr/actualite/actualite31.htm

http://audentia-gestion.fr/actualite/actualite32.htm

http://audentia-gestion.fr/actualite/actualite33.htm

http://audentia-gestion.fr/actualite/actualite34.htm

http://audentia-gestion.fr/actualite/actualite35.htm

http://audentia-gestion.fr/actualite/actualite36.htm

http://audentia-gestion.fr/actualite/actualite37.htm

http://audentia-gestion.fr/actualite/actualite38.htm

http://audentia-gestion.fr/actualite/actualite39.htm

http://audentia-gestion.fr/actualite/actualite4.htm

http://audentia-gestion.fr/actualite/actualite40.htm

http://audentia-gestion.fr/actualite/actualite41.htm

http://audentia-gestion.fr/actualite/actualite42.htm

http://audentia-gestion.fr/actualite/actualite43.htm

http://audentia-gestion.fr/actualite/actualite44.htm

http://audentia-gestion.fr/actualite/actualite45.htm

http://audentia-gestion.fr/actualite/actualite46.htm

http://audentia-gestion.fr/actualite/actualite47.htm

http://audentia-gestion.fr/actualite/actualite48.htm

http://audentia-gestion.fr/actualite/actualite49.htm

http://audentia-gestion.fr/actualite/actualite5.htm

http://audentia-gestion.fr/actualite/actualite50.htm

http://audentia-gestion.fr/actualite/actualite51.htm

http://audentia-gestion.fr/actualite/actualite52.htm

http://audentia-gestion.fr/actualite/actualite53.htm

http://audentia-gestion.fr/actualite/actualite54.htm

http://audentia-gestion.fr/actualite/actualite55.htm

http://audentia-gestion.fr/actualite/actualite56.htm

http://audentia-gestion.fr/actualite/actualite57.htm

http://audentia-gestion.fr/actualite/actualite58.htm

http://audentia-gestion.fr/actualite/actualite59.htm

http://audentia-gestion.fr/actualite/actualite6.htm

http://audentia-gestion.fr/actualite/actualite60.htm

http://audentia-gestion.fr/actualite/actualite61.htm

http://audentia-gestion.fr/actualite/actualite62.htm

http://audentia-gestion.fr/actualite/actualite63.htm

http://audentia-gestion.fr/actualite/actualite64.htm

http://audentia-gestion.fr/actualite/actualite65.htm

http://audentia-gestion.fr/actualite/actualite66.htm

http://audentia-gestion.fr/actualite/actualite67.htm

http://audentia-gestion.fr/actualite/actualite68.htm

http://audentia-gestion.fr/actualite/actualite69.htm

http://audentia-gestion.fr/actualite/actualite7.htm

http://audentia-gestion.fr/actualite/actualite70.htm

http://audentia-gestion.fr/actualite/actualite71.htm

http://audentia-gestion.fr/actualite/actualite72.htm

http://audentia-gestion.fr/actualite/actualite8.htm

http://audentia-gestion.fr/actualite/actualite9.htm

http://audentia-gestion.fr/actualite/actualitebandeau728.htm

http://audentia-gestion.fr/actualite/actualiteboutiquedutimbre.htm

http://audentia-gestion.fr/actualite/biosig-up-10-on-encouraging-data-on-covidminus-19-antiviral.htm

http://audentia-gestion.fr/actualite/colissimo.htm

http://audentia-gestion.fr/actualite/cookiechoices.js

http://audentia-gestion.fr/actualite/farnell-Imbattable.htm

http://audentia-gestion.fr/actualite/farnellactualitebandeau728.htm

http://audentia-gestion.fr/actualite/fnacactualitebandeau728.htm

http://audentia-gestion.fr/actualite/gilead-says-draft-of-coronavirus-treatment-results-contain-inappropriate-characterization-and-are-inconclusive.html

http://audentia-gestion.fr/actualite/gouvernementFR-Twitter.htm

http://audentia-gestion.fr/actualite/grosbillactualitebandeau728.htm

http://audentia-gestion.fr/actualite/hypertension-patients-diabetics-at-high-risk-for-covid-19.html

http://audentia-gestion.fr/actualite/loutremer-Twitter.htm

http://audentia-gestion.fr/actualite/maillot-collector-de-Thibaut-Pinot.html

http://audentia-gestion.fr/actualite/particulier-vend-51-m2-VERSAILLES.htm

http://audentia-gestion.fr/actualite/planetencre.htm

http://audentia-gestion.fr/actualite/sinscrirenewsletter.htm

http://audentia-gestion.fr/actualite/sitemapactualite.xml

http://audentia-gestion.fr/actualite/telecharger.php

http://audentia-gestion.fr/actualite/tetherless-pulse-oximeter-can-monitor-covid-19-patients-home.html

MENU EN CE MOMENT EN CE MOMENT Coronavirus : Les Dernières Informations LCI À Vos Côtés Pendant L'épidémie Nos Conseils Face Au Confinement SOS Villages RUBRIQUES DIRECTS REPLAY MÉTÉO JEUX PLUS LCI INNO GREEN SCIENCES HIGH-TECH VIVA TECHNOLOGY Innovation : le masque réutilisable à l'infini de Michelin Innovation : le masque réutilisable à l'infini de Michelin PUB : Votre vidéo dans un instant Pause Toggle MuteVolume Toggle Fullscreen HIGH-TECH SUIVRE De nombreux Français pourraient porter bientôt les masques fabriqués par les ingénieurs de Michelin et par ceux du commissariat aux énergies atomiques. Son prototype est réutilisable à l'infini et jugé cinq fois plus rentable que les fameux FFP2. 25 avr. 20:15 - Pour l'instant, seuls les masques en tissu sont disponibles pour le grand public dans l'Hexagone. Mais des entreprises travaillent également sur des prototypes beaucoup plus performants. C'est notamment le cas du groupe Michelin, plutôt spécialisé dans les pneus. Son modèle 100% Français est composé d'une partie masque qui va servir à l'infini et une partie filtre, utilisable et lavable 20 fois. Ce prototype qui coûtera 28 euros s'est déjà prévendu à 350 000 exemplaires. TOUTE L'INFO SUR LE WE 20H LIRE AUSSI CORONAVIRUS - Suivez les dernières actus en direct sur l'épidémie Déconfinement : un plan, six chapitres Coronavirus : un respirateur "made in France" produit à un coût défiant toute concurrence Ce sujet a été diffusé dans le journal télévisé de 20H du 25/04/2020 présenté par Anne-Claire Coudray sur TF1. Vous retrouverez au programme du JT de 20H du 25 avril 2020 des reportages sur l'actualité politique économique, internationale et culturelle, des analyses et rebonds sur les principaux thèmes du jour, des sujets en régions ainsi que des enquêtes sur les sujets qui concernent le quotidien des Français. Mis à jour : Hier à 18:02Créé : samedi dernier à 20:15 CONTENUS SPONSORISÉS Jusqu'où peut-on faire des courses sans risquer une amende ? Jusqu'où peut-on faire des courses sans risquer une amende ? Sponsorisé par Les top vidéos du moment Douleurs cervicales ? Les habitants de Taverny ne peuvent plus se passer de cet appareil Douleurs cervicales ? Les habitants de Taverny ne peuvent plus se passer de cet appareil Sponsorisé par NeckRelax Avec l’arrivée de cette version de Windows 10, Microsoft mise tout sur les PC portables Avec l’arrivée de cette version de Windows 10, Microsoft mise tout sur les PC portables Sponsorisé par 01net A VOIR AUSSI Droguée, séquestrée et violée : la chanteuse Duffy raconte sa disparition médiatique Droguée, séquestrée et violée : la chanteuse Duffy raconte sa disparition médiatique Droguée, séquestrée et violée : la chanteuse Duffy raconte sa disparition médiatique "Beaucoup de gens vont sortir fracassés de cette crise", alerte le Secours catholique "Beaucoup de gens vont sortir fracassés de cette crise", alerte le Secours catholique "Beaucoup de gens vont sortir fracassés de cette crise", alerte le Secours catholique Patrick Bruel et CharlElie Couture se remettent du coronavirus Patrick Bruel et CharlElie Couture se remettent du coronavirus Patrick Bruel et CharlElie Couture se remettent du coronavirus À CONSULTER AUSSI Wyritol lingettes Wyritol lingettes Sponsorisé par JPG Le mystère de l'orgasme féminin enfin résolu...grâce aux lapins Le mystère de l'orgasme féminin enfin résolu...grâce aux lapins Le mystère de l'orgasme féminin enfin résolu...grâce aux lapins Nettoyeur haute pression 19,99€ - Nettoyez voiture, maison, trottoirs, mur, toiture,... Nettoyeur haute pression 19,99€ - Nettoyez voiture, maison, trottoirs, mur, toiture,... nettoyeur-haute-pression SUR LE MÊME SUJET LE WE 20H PARLONS… HIGH TECH 03:08 Fermeture des marchés : les producteurs s'organisent 01:20 Les titres du JT de 20H 01:15 Attaque au couteau à Romans-sur-Isère : que sait-on de l'assaillant ? 03:20 Coronavirus : une très lente réadaptation du patient après la réanimation 02:21 Les passagers du Zaandam enfin à quai 02:18 Pénurie de masques : les masques "alternatifs" et les écharpes sont-ils efficaces pour se protéger ? ET AUSSI Les titres du JT de 13H Les titres du JT de 13H Contrôles de police : le point sur la situation à la porte d'Orléans Les prévisions météo du JT de 13 heures du 31 mars 2020 L'édito Aphatie : "Cette mission d'information ressemble beaucoup à une commission d'enquête" Fraude au chômage partiel : le gouvernement renforce les sanctions LIRE ET COMMENTER ACCUEIL>HIGH-TECH FIL INFO EN DIRECT LA PANDÉMIE DE COVID-19 12:26 A la veille des annonces d'Edouard Philippe, La France Insoumise propose son propre plan de déconfinement 12:22 VIDÉO - Première apparition en public de Boris Johnson depuis sa guérison du Covid-19 11:40 Présentation du plan de déconfinement : l'opposition critique la méthode du gouvernement 10:29 EN DIRECT - Coronavirus : +7,1% de chômeurs au mois de mars, du jamais-vu 10:17 Le PS pleure Henri Weber, figure de Mai-68, mort du coronavirus TOUT LE FIL INFO A VOIR, A LIRE Secteur automobile : des voitures à prix cassés pour éviter l'effondrement des ventes ?Secteur automobile : des voitures à prix cassés pour éviter l'effondrement des ventes ? Secteur automobile : des voitures à prix cassés pour éviter l'effondrement des ventes ? Ce rituel simple aide à brûler la graisse du ventre et des cuisses (faites ceci tous les jours) Ce rituel simple aide à brûler la graisse du ventre et des cuisses (faites ceci tous les jours) Brûleur Oméga Comment protéger son épargne en cas de crise économique ou sanitaire ? Comment protéger son épargne en cas de crise économique ou sanitaire ? capital-placement.info Coronavirus : 8500 respirateurs produits pour rien ? Le gouvernement se défend02:53Coronavirus : 8500 respirateurs produits pour rien ? Le gouvernement se défend Coronavirus : 8500 respirateurs produits pour rien ? Le gouvernement se défend Coronavirus : dans la peau du Dr Anthony Fauci, Brad Pitt s'en prend avec humour à Donald Trump02:07Coronavirus : dans la peau du Dr Anthony Fauci, Brad Pitt s'en prend avec humour à Donald Trump Coronavirus : dans la peau du Dr Anthony Fauci, Brad Pitt s'en prend avec humour à Donald Trump VIDÉO - Inès, l’infirmière de "Koh-Lanta" : "Travailler sans matériel au début de la pandémie, ça m'a mise hors de moi"03:12VIDÉO - Inès, l’infirmière de "Koh-Lanta" : "Travailler sans matériel au début de la pandémie, ça m'a mise hors de moi" VIDÉO - Inès, l’infirmière de "Koh-Lanta" : "Travailler sans matériel au début de la pandémie, ça m'a mise hors de moi" LES ACTUS DU MOMENT DÉCONFINEMENT : LE CASSE-TÊTE DE L'EXÉCUTIF NOS CONSEILS FACE AU CONFINEMENT CORONAVIRUS : L'IMPACT ÉCONOMIQUE DE LA PANDÉMIE CORONAVIRUS : LA PANDÉMIE QUI BOULEVERSE LA PLANÈTE LES SOLDES D'ÉTÉ 2020 TOUS LES SUJETS NEWSROOM International Planète Météo Politique Police Justice Terrorisme Football Autres sports Insolite Résultats Élections Municipales 2020 SOCIÉTÉ Social Population Education Santé DAILY Famille Vie de couple Psycho Loisirs MA SANTÉ Bien-être Nutrition Beauté CULTURE People Médias Sorties ÉVASION Régions Voyages SOS Villages CONSO Mon argent Immobilier Automobile Shopping WORK Open-space Emploi INNO Sciences Green High-tech PODCAST Happy Work Futur & Co Impact Positif Les gens qui lisent sont plus heureux MYTF1 TF1 TMC TFX TF1 SÉRIES-FILMS Actualité en continu SOS VILLAGES Direct SUIVEZ-NOUS PARTENAIRE DE LCI Copyright © 2020 Mentions légalesConditions générales d'utilisationPolitique de protection des données du service LCICookiesEspace PresseAccessibilitéLa médiatrice vous répondNewsletter et alertes Acces direct au contenuAcces direct au menu Toms Guide : actualités high-tech et logiciels ACTU GUIDE D’ACHAT TEST DOSSIER TUTO FORUM TÉLÉCHARGER Accéder à mon compte Rechercher THÈMES : Smartphones PC portables Apps gratuites Jeux vidéo Windows Accès Internet Cinema Bons plans Voir plus Accueil » Actualité » Tesla : l’Autopilot se met à jour pour reconnaître et réagir aux feux tricolores et aux panneaux Stop Tesla : l’Autopilot se met à jour pour reconnaître et réagir aux feux tricolores et aux panneaux Stop par BRUNO CLAIRET, le 26 avril 2020 15:27 Facebook Twitter Partager par emailImprimer Tesla met à jour son système de conduite automatisée. L’Autopilot détecte désormais les feux tricolores et les panneaux Stop pour adapter la vitesse du véhicule. La fonctionnalité apporte un niveau de sécurité supplémentaire, mais reste en bêta. Elle commet encore trop d’erreurs. Tesla vient de déployer une mise à jour de son assistant de conduite. Avec le patch 2020.12.6, l’Autopilot est maintenant capable de reconnaître les feux de signalisation et les panneaux Stop. Une fonctionnalité qui marque une étape supplémentaire vers la conduite entièrement autonome qu’Elon Musk avait déjà annoncée pour l’année dernière. En accès anticipé depuis deux mois, le patch est désormais disponible pour tous les clients américains. Une mise à jour est prévue pour les autres pays, mais on ignore encore le planning exact de Tesla. La firme doit en effet l’adapter à leurs signalétiques spécifiques avant d’envisager une distribution plus large cet été. Image 1 : Tesla : l’Autopilot se met à jour pour reconnaître et réagir aux feux tricolores et aux panneaux Stop Crédit : Dirty Tesla La note de version précise que la mise à jour permet d’identifier les feux tricolores et les panneaux Stop pour induire de nouveaux comportements aux intersections. Lorsqu’un feu tricolore est vert, orange, clignotant ou éteint, le véhicule ralentit automatiquement. S’il repère un feu rouge ou un panneau Stop, il ralentit et s’arrête. Une pression sur le boîtier de vitesse ou l’accélérateur permet d’indiquer que le véhicule peut poursuivre sa route sans danger. Tesla rappelle que la fonctionnalité est encore en bêta, et qu’il arrive parfois qu’elle n’interprète pas correctement une situation. Il convient donc de rester vigilant, les premiers retours des possesseurs de Tesla le confirment. L’Autopilot progresse, mais commet encore trop d’erreurs pour être autonome Dans sa première version, la fonctionnalité provoquait l’arrêt des Tesla même au feu vert. La mise à jour est beaucoup plus fiable, et les premiers essais montrent qu’elle apporte un niveau de sécurité supplémentaire. Elle reste néanmoins en version bêta. La chaîne YouTube Dirty Tesla a mis en ligne une série de vidéos qui illustre le comportement de l’Autopilot dans différentes situations. Le système réagit plutôt bien, mais il commet encore des erreurs. Tesla va bien sûr l’améliorer, mais la route semble encore longue avant d’obtenir un système de conduite entièrement autonome. Comme à son habitude, Elon Musk fait preuve d’un optimisme à toute épreuve, il vient en effet de confirmer que ses taxis autonomes seront prêts pour être déployés cette année. Votre Tesla se garera automatiquement avant fin 2020, c’est le souhait d’Elon Musk Source : Teslarati Thèmes : tesla, Voiture Electrique La maison de Christian Clavier choque le monde entier, la preuve en image ! PsychicMonday | Sponsorisé La femme de Marc Lavoine choque le monde entier, la preuve en image ! LawyersFavorite | Sponsorisé La gélule brûle-graisse dont tout le monde parle Brulafine.com | Sponsorisé Michel Drucker: sa maison va vous piquer les yeux Boite a Scoop | Sponsorisé Le fils de Sophie Marceau nous fait halluciner aujourd'hui ! Life Indigo | Sponsorisé 15 utilisations du dentrifice que vous ne connaissez pas ! Que Des Astuces | Sponsorisé Conservée dans une bulle depuis 1997, une BMW 740i neuve est mise aux enchères Tom's guide Tesla : l’Autopilot détecte un piéton sur l’autoroute et écrase le frein Tom's guide Réagissez avatar Démarrer la discussion... Suivre la discussion Article Liés 25/04 Kia accélère l’électrification de sa gamme avec un crossover inédit prévu pour fin 2021 24/04 Un moteur Tesla se retrouve dans un Land Rover Defender 24/04 Ferrari doit présenter deux modèles cette année, et pourquoi pas une électrique ? 23/04 Tesla : qu’arrive-t-il si l’on sort d’une Model 3 en Autopilot ? 22/04 Taycan : Porsche prépare une version d’entrée de gamme pour sa sportive électrique 22/04 Tesla Model Y : ses places dans le coffre sont-elles utilisables ? Nos derniers dossiers Articles les plus lus 1 PS4 : les 15 meilleurs jeux gratuits à télécharger sur le PlayStation… 2 Quels smartphones Huawei auront les mises à jour d’Android pour le… 3 Tesla : qu’arrive-t-il si l’on sort d’une Model 3 en Autopilot ? 4 The Walking Dead : comment Jadis aurait-elle affronté Alpha ? 5 Kia accélère l’électrification de sa gamme avec un crossover inédit… Abonnez-vous à notre newsletter E-mail * SUIVEZ-NOUS Facebook Twitter Youtube InstagramRSS À PROPOS Mentions légales et CGU Confidentialité et Cookies Préférences Cookies ENTREPRISE Qui sommes nous Contact © 2020 Galaxie Media Tous droits réservés PHONANDROID 04/26 Windows 10 : Microsoft fait de la pub pour Edge dans la barre de recherche et le site d’Outlook 04/26 Non, OnePlus ne va pas licencier 80% de son personnel en Europe pendant la crise 04/25 Netflix : les séries et films à regarder ce week-end 04/25 Android : l’enregistrement des appels audio arrive bientôt, mais pas pour tout le monde Tous les bons plans Vie du net EN CE MOMENT : Meilleures tablettes Néobanques Confinement PC portables Casques-micro FORUM CONNEXION Les Numériques TÉLÉPHONIE TV & SON MAISON INFORMATIQUE PHOTO LOISIRS VOITURES & CO TESTS NEWS TÉLÉCHARGEMENT COMPARATIFS Publicité AccueilVie du net Facebook investit plus de 5 milliards dans le principal opérateur 4G indien et affiche ses ambitions sur le commerce en ligne Par Johann Breton Publié le 26/04/20 à 11h24 Partager : L'opérateur Jio, qui a démocratisé l'accès à la 4G en Inde, vient de laisser entrer Facebook à son capital. Quatre ans après l'échec de l'initiative Internet.org, le réseau social consolide ainsi sa position centrale dans la vie numérique indienne. © iStock © iStock Dans une relative discrétion, Facebook a annoncé cette semaine le deuxième plus gros investissement de son histoire après l'acquisition de WhatsApp. Certes loin des plus de 20 milliards de dollars finalement dépensés pour croquer le service de messagerie, le réseau social vient de signer un chèque de 5,7 milliards de dollars (soit environ 5,3 milliards d'euros) pour s'offrir 9,9 % de Jio Platforms, groupe indien qui détient notamment l'opérateur éponyme. Dans le pays, Jio est tout sauf un poids léger : il compte près de 400 millions de clients sur ses offres mobiles, lancées à prix très bas et exclusivement sur le réseau 4G en 2015. Cela représente approximativement deux tiers du marché, et l'opérateur passe maintenant à l'offensive sur la fibre. Ni Facebook ni l'opérateur ne se cachent concernant les raisons de ce rapprochement. Le réseau social, de son côté, voit dans la transaction une voie royale pour façonner un peu plus les habitudes des mobinautes indiens, qui sont déjà largement acquis à la cause de WhatsApp (400 millions d'utilisateurs) et d'Instagram. Dans son communiqué, la firme parle notamment de développer l'activité des petites entreprises, avec en toile de fond la démocratisation de WhatsApp en tant que plateforme de commerce en ligne, en particulier derrière la solution de Jio, JioMart. Jusqu'ici, Amazon et Flipkart se taillaient la part du lion sur le marché indien (chacun plus de 30 % du marché). Jio et son actionnaire principal, Reliance Industries, saluent pour leur part l'arrivée d'un partenaire expert dans l'analyse et la monétisation des données, n'hésitant pas à souligner la masse que représente l'audience cumulée de tous les services des deux groupes en Inde. Aucun plan concret n'aurait encore été défini, mais Reliance Industries serait très ouvert aux suggestions et nouvelles idées envisageables avec le soutien de Facebook, les opportunités couvrant un très vaste spectre du secteur de l'éducation à celui de la santé. Facebook s'achète un retour en bonnes grâces Pour Facebook, cette entrée au capital de Jio Platforms est par ailleurs doublement stratégique. En effet, le réseau social a des relations très difficiles avec le gouvernement indien depuis 2015 et l'épisode Internet.org (devenu Free Basics). Pour rappel, Facebook offrait gratuitement un accès à Internet via réseau mobile, mais restreint à une poignée de services – dont, bien évidemment, son réseau social. Les autorités n'avaient pas apprécié cette vision tronquée d'Internet et, début 2016, avaient de fait banni le service en s'appuyant sur les arguments de la neutralité du Net et d'une pratique discriminatoire pour les opérateurs. En injectant plusieurs milliards en Inde, Facebook se rachète en quelque sorte une image auprès des mêmes autorités, mais la firme gagne surtout un allié colossal. Reliance Industries est un titan, la première capitalisation d'Inde, dont les activités ne s'arrètent pas aux télécommunications, mais incluent aussi l'énergie (pétrole) ou encore le commerce en général. Son patron est, en outre, l'homme le plus riche d'Asie, et il ne se prive pas de conseiller le gouvernement indien. Autant dire que le poids politique de ce nouveau partenaire devrait garantir à Facebook une certaine tranquilité dans ses activités locales et fournir un levier de choix si, d'aventure, des négociations devaient être nécessaires avec les autorités. Tag associé : Partager : JOHANN BRETON Rédacteur noté 3 étoiles lors de son test. Très grande autonomie, mauvais en photo. Ergonomie correcte. Néobanques : le top 10 Les Numériques-Challenges Play Video Publicité ACTUALITÉ Faut-il encore commander sur Amazon, Cdiscount, Fnac-Darty et autres boutiques en ligne ? 29 VIE DU NET Faut-il encore commander sur Amazon, Fnac Darty, Cdiscount et les autres boutiques en ligne ? Hier à 14:12 VOIR TOUTES LES ACTUALITÉS DOSSIER CES 2020 : retour sur les grandes tendances et les innovations les plus marquantes VIE DU NET il y a 3 mois CES 2020 – Retour sur les grandes tendances et les innovations les plus marquantes Dossier par Mathieu Chartier VOIR TOUS LES DOSSIERS Suivez-nous Contact FAQ La rédaction Comparaison de prix Préférences cookies Abonnez-vous à la Numsletter Mon adresse mail Vie privée Cookies Conditions Générales d’Utilisation Tout droits réservés © 2020 Sunday, April 26 2020 Trending Automatic Self-Piercing Rivets Market Global Market Share, Regional Growth Analysis, Upcoming Trends, Technology Updates and Development Analysis Research Report 2026 Contact Bandera County Courier Business Health Science Technology World Search for Home/Health/Latest Report on Healthcare CRM Market with a Growing CAGR During 2020-2027 | Top Companies: IBM, salesforce.com, Siemens Healthineers Health Latest Report on Healthcare CRM Market with a Growing CAGR During 2020-2027 | Top Companies: IBM, salesforce.com, Siemens Healthineers him April 25, 2020 Healthcare CRM Healthcare CRM The report titled, “Healthcare CRM Market” boons an in-depth synopsis of the competitive landscape of the market globally, thus helping establishments understand the primary threats and prospects that vendors in the market are dealt with. It also incorporates thorough business profiles of some of the prime vendors in the market. The report includes vast data relating to the recent discovery and technological expansions perceived in the market, wide-ranging with an examination of the impact of these intrusions on the market’s future development. Healthcare CRM Market research reports growth rates and the market value based on market dynamics, growth factors. The complete knowledge is based on the latest innovations in the industry, opportunities, and trends. In addition to SWOT analysis by key suppliers, the report contains a comprehensive market analysis and major player’s landscape. Ask for Sample Copy of This Report: https://www.healthcareintelligencemarkets.com/request_sample.php?id=57690 Top Key Players Included in This Report: IBM, salesforce.com, Siemens Healthineers, SAP, Accenture, Oracle, Microsoft, Amdocs Ltd., Anthelio Healthcare Solutions, AllScripts Healthcare Solutions Inc., NetSuite, Cerner. Major highlights of this research report: In-depth analysis of the degree of competition across the globe. Estimation of Healthcare CRM Market values and volumes. Healthcare CRM Market analysis through industry analysis tools such as SWOT and Porter’s five analysis. Detailed elaboration on global market value, volume, and penetration. Healthcare CRM Market growth projections. Detailed description on development policies and plans. Analytical study on drivers, restraints, opportunities, hindrances, inadequacies, challenges and strengths. The report on the Healthcare CRM Market has newly added by IT Intelligence Markets to its huge repository. The global market is expected to increase from 2020 to 2027. Primary and secondary research methodologies have been used for curating this research report. Get Discount on This Report: https://www.healthcareintelligencemarkets.com/ask_for_discount.php?id=57690 The competitive landscape of the Healthcare CRM Market is described in terms of the players and their statistics. For each key player, the report reveals production rates, costing, overall pricing, revenue generation, and market share within the Healthcare CRM Market. The research on the Healthcare CRM Market will be applicable to investors, business owners, industry experts, and various c level peoples. Profiling of the several top-level industries has been included in this informative report. *If you have any special requirements, please let us know and we will offer you the report as per your requirements. For Any Customization, Ask Our Experts: https://www.healthcareintelligencemarkets.com/enquiry_before_buying.php?id=57690 Table of Contents: Healthcare CRM Market Overview Economic Impact on Industry Market Competition by Manufacturers Production, Revenue (Value) by Region Supply (Production), Consumption, Export, Import by Regions Production, Revenue (Value), Price Trend by Type Market Analysis by Application Manufacturing Cost Analysis Industrial Chain, Sourcing Strategy and Downstream Buyers Marketing Strategy Analysis, Distributors/Traders Market Effect Factors Analysis Healthcare CRM Market Forecast About Us: HealthCare Intelligence Markets Reports provides market intelligence & consulting services to a global clientele spread over 145 countries. Being a B2B firm, we help businesses to meet the challenges of an ever evolving market with unbridled confidence. We craft customized and syndicated market research reports that help market players to build game changing strategies. Besides, we also provide upcoming trends & future market prospects in our reports pertaining to Drug development, Clinical & healthcare industries. Our intelligence enables our clients to take decisions with which in turn proves a game-changer for them. We constantly strive to serve our clients better by directly allowing them sessions with our research analysts so the report is at par with their expectations. Contact Us: Marvella Lit Address: 90, State Office Center, 90, State Street Suite 700, Albany, NY 12207 Email: sales@healthcareintelligencemarkets.com Web: www.healthcareintelligencemarkets.com Phone: +44-753-712-1342 FacebookTwitterLinkedInStumbleUponRedditShare via EmailPrint him Related Articles April 22, 2020 5 Massive Growth of Natural Killer (NK) Cell Therapeutics Market to Witness a Pronounce Growth at CAGR during 2020-2027| Chipscreen Biosciences (China), Affimed NV (Netherlands), Altor BioScience Corporation (USA), Innate Pharma SA Medical 3D Printing Market February 27, 2020 28 Trending 2020 Medical 3D Printing Market Worldwide Survey with Top growing Companies: Arcam AB, Autodesk, Stratasys, ExOne Company, H Intressenter AB, Optomec, Organovo Holdings, Voxeljet AG Anti-Aging Products and Therapies Market February 25, 2020 5 Anti-Aging Products and Therapies Market Competitive Dynamics & Global Outlook 2027| Key Players Allergan, Ipsen, Lanzhou Institute, Corneal(Allergan), Galdermal Medical Oxygen Concentrators February 24, 2020 6 Growth Hacking Strategies for Global Medical Oxygen Concentrators MARKET with Report during year 2020-2027 with Major Key Players: Chart Industries, Inogen, Invacare Corporation Aller au contenu principal Rechercher Politique International Société Vox Économie Sport Culture Voyage Style Madame Figaro Live Se connecter Lire Tech & web en PDF en ligne Lire le journal Abonnez-vous 1€ le premier mois ActualitésStart-upTestsPratiqueJeux vidéos AccueilTech & Web Essais cliniques : l’acquisition de Medidata, le pari gagnant de Dassault Systèmes La crise actuelle souligne la pertinence de la plus grosse acquisition réalisée par le groupe français. Par Elsa Bembaron Publié hier à 18:58, mis à jour hier à 18:58 Dassault Systèmes Nul triomphalisme chez Bernard Charlès, le PDG de Dassault Systèmes, à l’occasion de la présentation des résultats du premier trimestre 2020. Mais une pointe de satisfaction de disposer des bons outils au bon moment. Le groupe a déboursé près de 6 milliards de dollars pour mettre la main sur Medidata. «Il y a à peine six mois nous avons fait cet investissement pour faire évoluer les processus collaboratifs dans la santé, développer les jumeaux numériques... Aujourd’hui, nous sommes au centre de la situation pour les essais cliniques. Près de 60% des essais cliniques en cours, dont ceux sur le Covid-19, sont faits sur Medidata», constate Bernard Charlès. La pandémie place sur le devant de la scène de nouveaux sujets et apporte un nouvel éclairage sur la stratégie de Dassault Systèmes. Medidata est notamment reconnu pour les «bras de contrôle synthétiques». Cette méthode est utilisée dans le cadre d’essais cliniques. Traditionnellement, deux groupes de patients sont constitués. La moitié des patients se voient administrer une thérapie, l’autre un placebo. «Le bras de contrôle synthétique permet de réduire la taille des cohortes de patients. Une population virtuelle est établie, en lien avec le réel. Cela permet aussi de mieux cibler les profils qui ont le maximum de chances de bénéficier de l’efficacité d’un traitement», explique Bernard Charlès. L’objectif final étant de gagner en efficacité, en pertinence et en rapidité. Les défis posés par le Covid-19 mettent en avant ces impératifs. Sponsorisé par FRANFINANCE Faites signer électroniquement vos contrats entreprises depuis Flashlease Faites signer électroniquement vos contrats Entreprises depuis Flashlease ! Découvrez notre solution de signature électronique ! #digitalbanking #digital #finance #digitalisation #efficacité FRANFINANCE VOIR PLUS Des équipes à 150% La branche santé de Dassault Systèmes n’est pas la seule à avoir été très sollicitée avec la crise. «Nos clients industriels nous ont demandé de l’aide pour mettre en place des solutions de télétravail, ajoute Bernard Charlès. Nos équipes travaillent à 150%». Non seulement Dassault Systèmes n’a pas eu recours au chômage partiel, mais en plus, le groupe s’engage à conserver tous ses salariés, même s’il peut «y avoir une redirection de certaines activités». Pour son PDG, le Dassault Systèmes qui sortira de la crise ne sera plus le même que celui qui y est entré. Il n’a pas remisé pour autant ses objectifs de croissance, même s’il les a revus à la baisse. «Notre modèle est résiliant, avec 85% de nos revenus récurrents», mentionne Bernard Charlès, même s’il s’attend à une nouvelle vague de consolidation dans la sous-traitance aéronautique et automobile. Des opérations qui pourraient profiter à son groupe, puisque dans ce cas, les outils sont harmonisés. Au final, Dassault Système table sur une croissance de 14 à 15% contre un objectif de 24% auparavant. Les prévisions initiales de bénéfice net par action tablaient sur une croissance de 12%. Désormais, le groupe anticipe une stabilité, voire une progression de 2%. Au premier trimestre, le chiffre d’affaires du groupe a progressé de 17% , reflétant l’intégration de Medidata, à 1,13 milliard d'euro. La marge opérationnelle du groupe est passée de 22,5% à 13,3% un an plus tôt. Le groupe maintien son dividende à 0,70 euro par action. «Sans abaisser notre dividende, nous avons un taux de distribution de 30% quand de nombreux groupes sont encore au delà de 50%», mentionne Bernard Charlès. La rédaction vous conseille Dassault Systèmes met le cap sur la santé Dassault Systèmes change de dimension Bernard Charlès: «Nous vivons une nouvelle révolution industrielle» Avec Medidata, Dassault Systèmes réalise la plus grosse acquisition de son histoire Sujet DASSAULT SYSTEMES par Taboola Contenus Sponsorisés 5 entreprises qui développent un vaccin contre le coronavirus : laquelle sera la première à le commercialiser ? - eToro eToro Blog Post Ce nouveau placement à 7% qui séduit de plus en plus de Français Top Economie 14 formations à domicile financées à 100% L'École Française Nouveau 2020 : plus de conditions de revenus pour bénéficier des aides à l’isolation Mes Combles Gratuits + 55ans : Classement des meilleures mutuelles 2019 Meilleurtaux.com Le nouveau jeu de construction qui rend tout le monde accro. Pas d'installation Forge Of Empires - Jeu en ligne gratuit C’est sur ce site que les célibataires de plus de 50 ans trouvent l’amour à Versailles Nos Belles Années Découvrez la nouvelle Opel Corsa-e, élue Best Buy Car of Europe Opel France par Taboola Recommandé pour vous Confiné en Maine-et-Loire, Gérard Depardieu est «remonté contre Macron» Le Figaro Trouvez votre Volkswagen Tiguan d'occasion sur ParuVendu.fr ParuVendu La mystérieuse disparition de Kim Jong-un Le Figaro Premium 4 commentaires fafia le 24/04/2020 à 09:10 la maladie doit payer après un tel investissement ... nous n'en n'avons pas fini des virus à répétition !!! DORSAIS123 le 23/04/2020 à 20:14 Dassault un des derniers groupe debout ,issus de l'épopée des Bâtisseurs des"trente glorieuse") L’OTAN impose à l’Allemagne l’achat d’avions américains POUR renouveler une partie de sa flotte d’avions de chasse, quelque 45, F-18 de l’américain Boeing.Car l’OTAN l’exige, pour être en droit de transporter les bombes nucléaires mises à disposition par Washington,??? "Ça fait Flipper " Berlin est forcée de s’équiper au moins en partie en matériel américain au lieu de pouvoir choisir des avions européens.et devient dépendante des technologies,US. Déja Madame Lagarde militait aux États-Unis au Center for Strategic & International Studies (CSIS).Qu'elle co-présidait avec Zbigniew Brzezinski,la commission Action USA/UE/Pologne et suivait plus particulièrement le groupe de travail Industries de défense USA-Pologne (1995-2002)Bruce P. Jackson, fondateur(US Committee for Expand NATO).représentait les intérêts de l’avionneur Lockheed Martin,en avait été vice-président.c'est au travers des commissions présidées par Christine Lagarde que M. Jackson monta le contrat du siècle:la vente,04/2003, de 48 chasseurs F-16 Lockheed-Martin à la Pologne 3,5 milliards $.la logique eut voulu que Varsovie s’équipe de Mirage 2000-5 MK2 Dassault ou de Jas-39 Saab JPR92200 le 23/04/2020 à 19:34 Brillante société française de haute technologie qui mérite son succès : " le hasard ne favorise que les esprits préparés " (Pasteur) LIRE LES 4 COMMENTAIRES Chargement de l'article suivant... Plus de services L'actualité à ne pas manquer Résultats des élections Elections municipales 2020 Brexit : tout savoir Tension Iran-Etats Unis Crise politique italienne Mandat Donald Trump Corée-Du-Nord Actualité politique en temps réel Analyses, débats politiques et sociétaux Crise des prisons Programme TV Programme TV ce soir Programme TV en ce moment Programme TV TNT Séries Netflix, HBO, OCS et TV Election et photos Miss France Programme TV film Programme TV Canalsat Programme TV Free Programme TV SFR Actu people Sport Calendriers et résultats des matchs en direct Résultats, classement général Tour De France Ballon d'Or France Football Actualité cyclisme Actualité Euro 2020 Transferts football Classement Ligue 1 Jeux Olympiques Japon Tokyo 2020 Calendrier Euro 2020 Classement top 14 Madame Horoscope Guide du mariage Recettes de cuisine Brigitte Macron Actu mode Apéritif dînatoire Fête des mères Tendance bijoux Meghan Markle Gainer son corps Santé Fiches et guides des médicaments Astuces et conseils bien-être Santé et sexualité Index des maladies Conseils alimentation, nutrition et santé L'encyclopédie des organes Conseils en psychologie La pollution va t-elle nous tuer ? Apnée du sommeil : Comment mieux dormir ? 15 mythes sur les vertus des aliments Guide d'achat Guide d'achat maison et jardin Guide d'achat santé et beauté Guide d’achat high-tech Guide d'achat smartphones et tablettes Comment choisir le meilleur extracteur de jus ? Quelle est la meilleure montre connectée ? Quel est le meilleur home cinéma sans fil ? Comparatif semelle gel Quel épilateur électrique choisir ? Bons plans Education et orientation Résultats Bac Révisions du Bac Parcoursup Annuaire des écoles de commerce Les entreprises qui recrutent Trouver un stage Résultats Brevet des collèges Classement des écoles de commerce Trouver une alternance Agenda étudiant : JPO, salons… Culture Succession de Johnny Hallyday Sorties cinéma Guide arts et expositions Actualité musicale Actualité jeux-vidéo Citations et proverbes Réservation de spectacles et théâtre Sortir à Paris Histoire de France Langue française Codes promos et réductions Code promo Wish Code promo Cdiscount Code promo Apple Code promo eBay Code promo JD Sports Code promo Deliveroo Code promo Nike Code promo Sephora Code promo Red by SFR Code promo Asos Offres d'emploi Toutes les offres d'emploi Emploi à Paris Emploi à Lyon Emploi à Toulouse Emploi à Nantes Emploi à Bordeaux Emploi commercial Emploi contrôleur de gestion Emploi logistique Emploi communication Annonces immobilières Annonces immobilières Achat appartement Paris Achat appartement Nice Achat appartement Cannes Achat appartement Bordeaux Achat appartement Lyon Achat appartement Aix-en-provence Achat maison Bordeaux Achat maison Marseille Achat maison Montpellier Economie argent et finances Simulateur de seuil de richesse Actualité économique et analyses Impôts sur le revenu : simulateur Palmarès des villes où investir dans l'immobilier Studios et 2-pièces : les loyers ville par ville Calculer l'impôt à payer Barême des droits de succession et donation Indice de référence des loyers (IRL) En France, les hauts revenus sont-ils tous des «riches»? Carte familles nombreuses : jusqu’à 75 % de réduction sur les billets de train Essais cliniques : l’acquisition de Medidata, le pari gagnant de Dassault Systèmes Imprimer Partager 4 commentaires Paramétrer les cookiesPlan du siteConfidentialitéCGUCGVInfo cookiesCharteAide et contactMentions légalesAbonnementsNewsletterPublicitéSitemap Au format texte :

Skip to content COLE REPORTS COLE MARKET RESEARCH MARKET REPORTS INDUSTRY ANALYSIS MILITARY NEWS MORE Search for: SEARCH … GLOBAL OPTICAL NETWORKING AND COMMUNICATION MARKET RESEARCH ANALYSIS REPORT 2020 | HUAWEI TECHNOLOGIES CO (CHINA), NOKIA (FINLAND), CISCO APRIL 23, 2020SANTOSH Global Optical Networking and Communication Market Research Analysis Report 2020 | Huawei Technologies Co (China), Nokia (Finland), Cisco Optical Networking and Communication Market: Industry Growth ...An exclusive research report Global Optical Networking and Communication Market 2020 by Manufacturers, Countries, Type and Application, Forecast to 2026 added to the dataset of MarketsandResearch.biz especially covers global market top players, types, applications, pattern, and size. The report analyzes various market dynamics, the quickest and slowest market segments. The report gives autonomous data about the global Optical Networking and Communication market which includes analysis on size and patterns, inhibitors, elements, drivers, openings and difficulties, condition and arrangement, cost outline, porters five power investigation, and key organizations’ profiles including business review and improvement. The report assists the specialists to make choices dependent on the market investigation. The report presents segmentation of the global Optical Networking and Communication market by end-users, regional countries, product types and key manufacturers based on differentiable validation and industrial analysis. The document demonstrates an essential diagram of the business including definitions, groupings, applications and industry chain structure. On the basis of segments by manufacturers, this report focuses on the sales, price of each type, the average price, revenue, and market share, for key manufacturers. DOWNLOAD FREE SAMPLE REPORT: https://www.marketsandresearch.biz/sample-request/25435 Geographical data will help the reader understand the best performing regions. This report has added an examination and increment pace of the market in these districts covering: North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia etc.), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Our best analysts have surveyed the market report with the reference of inventories and data given by the key players: Huawei Technologies Co (China), Nokia (Finland), Cisco (US), Ciena (US), ADTRAN (US), Broadcom (US), Finisar (US), Fujitsu Optical Components (Japan), Infinera (US), ADVA Optical Networking (Germany), NEC (Japan), Juniper Networks (US), Ericsson (Sweden), Lumentum Operations (US), On the basis of product, this report displays the production, revenue, price, market share, and growth rate of market types split into: Fiber, Transceiver, Amplifier, Switch, Splitter, Circulator On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of market applications, includes: Telecom, Data Center, Enterprise, Others, Further, the report delivers a comprehensive analysis of industry trends along with the restraints, drivers, and opportunities in the market. The prominent vendors are also studied with SWOT analysis, fiscal overview and major developments. Different graphical presentation techniques such as charts, graphs, tables, and pictures have been used while making the report. The overall report includes research on historical and forecasts global Optical Networking and Communication market data, demand, application details, price trends, and company shares of the leading company by geography. ACCESS FULL REPORT: https://www.marketsandresearch.biz/report/25435/global-optical-networking-and-communication-market-2020-by-manufacturers-countries-type-and-application-forecast-to-2026 Why Purchase The Report? The researchers have offered projections about the global Optical Networking and Communication industry size based on value and volume in this part of the report. The report throws light on the recent industry developments and upcoming prospects that are likely to foster the overall market growth. The study gives reliable estimations regarding the growth potential of varied industry segments including product type, vertical, and application. Customization of the Report: This report can be customized to meet the client’s requirements. Please connect with our sales team (sales@marketsandresearch.biz), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements. About Us Marketsandresearch.biz is a leading global Market Research agency providing expert research solutions, trusted by the best. We understand the importance of knowing what global consumers watch and buy, further using the same to document our distinguished research reports. Marketsandresearch.biz has worldwide presence to facilitate real market intelligence using latest methodology, best-in-class research techniques and cost-effective measures for world’s leading research professionals and agencies. We study consumers in more than 100 countries to give you the most complete view of trends and habits worldwide. Marketsandresearch.biz is a leading provider of Full-Service Research, Global Project Management, Market Research Operations and Online Panel Services. Contact Us Mark Stone Head of Business Development Phone: +1-201-465-4211 Email: sales@marketsandresearch.biz Web: www.marketsandresearch.biz Post navigation Global Tea Packaging Market Research Analysis Report 2020 | Starship Technologies, Robby Technologies, Nuro, IncGlobal Sports & Energy Drinks Market Research Analysis Report 2020 | Red Bull, Monster, Rockstar, Pepsico, Big Red, Arizona, National santosh VIEW ALL POSTS BY SANTOSH PAGES About Us Contact Us Our Staff Privacy Policy Search for: Search … RECENT POSTS Global PEX Tubing Tools Market Size, Analytical Overview, Growth Factors, Demand, Trends And Forecast To 2026 Global Medical Sector Contract Electronic Manufacturing Market 2025 Top Manufacturers : Benchmark Electronics, FLEX, Celestica, Jabil Circuit, Sanmina, Nortech Systems Comprehensive Report on Load Bank Rental Market, Size, Share, Status and Forecast 2020-2026 | VIBSpECTRUM International, Aggreko, Vardha Technical Services LLC, Crestchic Limited, Power House Solar Panel Module Market (Impact of COVID-19) Growth, Revenue Status & Forecast Report 2025 | Trina Solar, Canadian Solar, JinkoSolar, JA Solar, Hanwha Q CELLS, First Solar, Yingli Green, SFCE, ReneSola Global Mechanical Energy Storage Market 2025 Top Manufacturers : Voith, Sulzer, DeWalt, Ingersoll Rand, Hitachi, Porter-Cable Theme of Rigorous Themes ABOUT US PRIVACY POLICY OUR STAFF CONTACT US Technology and gaming content trusted in North America and globally since 1999 8,575 Reviews & Articles | 60,314 News Posts CORONAVIRUS NEWS REVIEWS ARTICLES GUIDES GAMING ASK THE EXPERTS NEWSLETTER FORUMS Cases, Cooling & PSU CPUs, Chipsets & SoCs Motherboards Peripherals RAM Storage Video Cards Home News Video Cards NVIDIA is making something on 5nm, and we don't know what it is NVIDIA's mysterious 5nm product probably isn't a next-gen GPU, but TSMC is making something for Team Green on 5nm Anthony Garreffa | Apr 23, 2020 at 10:47 pm CDT (0 mins, 45 secs time to read) So, NVIDIA is making something on a fresh new 5nm node -- ordering TSMC to make it for the GeForce giant. Digitimes is reporting from its "industry sources" that NVIDIA is tapping TSMC's fresh new 5nm process node -- and it won't be for NVIDIA's next-gen Ampere GPU architecture or the GeForce RTX 3080 and GeForce RTX 3070 graphics cards. There is absolutely nothing else to this news other than Digitimes reporting that its sourcesh ave told them, that NVIDIA is making something new and mysterious on TSMC's new 5nm process node. It could be something for the Tegra side of things, or here's a wild rumor -- so prepare your salt shakers peeps -- the Nintendo Switch 2 SoC. Just throwing that out there. ASUS ROG STRIX GeForce RTX 2080TI Overclocked (ROG-STRIX-RTX-2080TI-O11G) Today Yesterday 7 days ago 30 days ago $1279.99 $1279.99 $1279.99 $1279.99 Buy * Prices last scanned on 4/23/2020 at 10:47 pm CDT - prices may not be accurate, click links above for the latest price. We may earn an affiliate commission. NEWS SOURCES:tomshardware.com, digitimes.com, s.thestreet.com ABOUT THE AUTHOR - Anthony Garreffa Anthony is a long time PC enthusiast with a passion of hate for games built around consoles. FPS gaming since the pre-Quake days, where you were insulted if you used a mouse to aim, he has been addicted to gaming and hardware ever since. Working in IT retail for 10 years gave him great experience with custom-built PCs. His addiction to GPU tech is unwavering. Similar News TSMC making 5nm ASICs for Bitmain and Canaan in 2020 AMD's next-gen Zen 4 could arrive on new 5nm or 6nm in 2021 TSMC makes progress on 5nm, should have 5nm chips in 2020 Intel promises process node leadership with 5nm... but in 2022+++ Apple's new iPhone will be powered by A14 chip made on 5nm from TSMC < PREVIOUS STORY: Intel's upcoming Ponte Vecchio Xe GPU turns up in add-in card form Related Tags NVIDIA TSMC 5nm NVIDIA 5nm node NVIDIA 5nm tech TSMC 5nm Nintendo Newsletter Subscription Latest News NVIDIA is making something on 5nm, and we don't know what it is Intel's upcoming Ponte Vecchio Xe GPU turns up in add-in card form NVIDIA, AMD purchase ALL excess capacity at TSMC for next-gen GPU/CPUs Intel revenue up 23% to $19 billion in Q1, operating income spikes 69% PlayStation 5 may use vapor chamber cooling, new Sony patent suggests View More News Latest Reviews Synology DS220j Two-Bay Consumer NAS Review ARCTIC Liquid Freezer II 280 CPU Cooler Review NZXT C850 Gold ATX Power Supply Review Seagate IronWolf 510 m.2 NAS SSD Review Star Wars: The Rise of Skywalker 4K Blu-ray Review View More Reviews Latest Articles GeForce Ti Showdown: GTX 980 Ti vs GTX 1080 Ti vs RTX 2080 Ti Best Gaming Monitors in 2020 (4K, UltraWide, 1440p, and 1080p) Best GPUs for PC Gaming in 2020 DOOM Eternal Benchmarked at 8K - Not Even The Devil Can Run This Half-Life: Alyx Buyers Guide: PC Hardware & VR Headset Recommendations View More Articles SITEMAP ADVERTISING ABOUT CONTACT RSS FEEDS PRIVACY POLICY © 1999-2020 Tweak Town Pty Ltd. All Rights Reserved. Read more: https://www.tweaktown.com/news/72034/nvidia-is-making-something-on-5nm-and-we-dont-know-what-it/index.html Search Reviews Smart Home & Gadgets Mobile Car Tech Online Science & Health Cameras Computing Gaming Entertainment Apple iPhone SE: Australian First Look Review Apple's iPhone SE: Every Phone Plan In Australia Every Telstra Plan For The New iPhone SE Apple iPhone SE: Australian First Look Review Tegan Jones | Apr 24, 2020, 2:25pm⋅ Filed to: apple Share Image: Tegan Jones/Gizmodo Australia Last year, Google turned the mid-range phone market on its head by introducing the ludicrously-priced and well-specced Pixel 3a. A few other brands have followed suit since then, but none have been quite as exciting as the new iPhone SE. Now it truly seems like flagship inclusions at lower price points are here to stay - and it's about damn time. The trend of $1,500 - $2,000 becoming the norm for new phones over the last few years has been bad for buyers. A new middle ground has been long overdue and we welcome it. But is the resurrected iPhone SE actually a good phone to buy in 2020? It's worth noting that I have only been playing with the iPhone SE for a day and a half, so these are my first impressions. Keep your eyes peeled for the full review next week. iPhone SE Specs But before we dive into things, here's a quick reminder of the specs. Display: 4.7 inches (1334 x 750) CPU: A13 Bionic Chip Storage: 64GB, 128GB, 256GB Battery: Up to 13 hours video playback, Qi wireless charging, fast charge Rear camera: 12MP (f/1.8) Front camera: 7MP (f/2.2) Video recording: 4K video up to 60 fps Water resistance: IP67 Size: 5.45 x 2.65 x 0.29 inches Weight: 148g Colour: Black, White, PROJECT(RED) iPhone SE Price In Australia In Australia the iPhone SE starts at $749 for the 64GB. 12GB will bring the price up to $829 and 256GB comes in at $999. You can grab one from the Apple Store now. If you'd prefer a plan, we have all of them compiled in one handy place for you. What's good about the iPhone SE? The iPhone SE is such a good size for smaller hands. Image: Tegan Jones/Gizmodo Australia iPhone SE Size In a world where 6.5-inch phones have become par for the course, it's refreshing for a premium phone manufacturer to offer something a bit smaller. While large phones screens are good for some things – streaming shows, reading, general browsing – they can also be incredibly uncomfortable. While I have gotten used to the iPhone 11 Pro Max, I have found the SE far more comfortable to use as a daily driver. The screen size isn't too small, the device nestles perfectly into my hand and it can actually fit into my lady pockets. A true miracle in 2020. And from a tactile perspective, it's the same as flagship phone – you won't find cheap plastic here. The material is lovely to touch and feels exactly the same as my 11 Pro Max, just smaller. While it isn't as small as the previous SE or some other older iPhones, I think that anyone upgrading from one of those previous generations will still be pleased – especially if you compare it to something like the Pro or Pro Max. iPhone SE Camera I'll have a far more in-depth dive into the iPhone SE camera in my full review, but I have a few initial thoughts. It's important to set your expectations if you're coming to the SE from a flagship device. It only has a single lens on the front and back, so it simply can't have the same functionality as a triple or quad camera array. That being said, it still pretty darn good so far, and this is primarily due to the processor. The iPhone SE has the same A13 bionic chip as iPhone 11 devices, which is a crazy move that I'm here for. The signal processor and N=neural engine in the A13 boosts the computational photography of the iPhone SE, which helps make up for what it lacks in hardware. But what does that actually mean when it comes to real world functionality? To put it simply, the single camera lenses are more capable thanks to the processor and software. The SE has Smart HDR, optical image stabilisation, subject recognition and the ability to capture clearer faces. It's also able to offer the same six lighting affects in portrait mode as the iPhone 11, as well as depth control adjustment you usually need a second lens for. When it comes to video, the rear camera is still able to capture 4K and 30 fps with cinematic stabilisation. As for the selfie cam, you still get the lovely bokeh effect – the soft, out-of-focus background in photos – of pricier iPhones thanks to the inclusion of monocular depth estimation. So far I have mostly messed around with the portrait and regular photo modes - and they really do a great job for single lenses. Sure, they're not as good as the iPhone 11 Pro Max, but at a price point of $750 - $1000 that was never going to happen. Here are a few comparisons between the iPhone SE and iPhone 11 Pro Max: iPhone SE Regular Photo Mode There's a noticeable different between the iPhone SE (left) and iPhone 11 Pro Max (right) in terms of brightness, sharpness and warmth. However, some of this could be brought back into the final product with some editing. iPhone SE Portrait Mode Left: iPhone SE, Right: iPhone 11 Pro Max iPhone SE Low Light Camera The iPhone SE (left) doesn't have a dedicated night mode like the iPhone 11 Pro Max (right) but it's low-light capabilities seem quite decent so far. iPhone SE Selfies Left: iPhone SE, Right: iPhone 11 Pro Max If you want to best camera phone on the market, the iPhone SE is not what you should opt for. But so far, I'm quite impressed and I'm looking forward to putting it through its paces more. What's not so good about the iPhone SE? Image: Tegan Jones/Gizmodo Australia iPhone SE Battery Life Unlike Android manufacturers, Apple doesn't reveal its battery sizes - but we do know that it's smaller than any device in the iPhone 11 lineup. For example, Apple quotes the SE as having up to 13 hours of video playback, where as the baseline iPhone 11 has up to 17. It didn't take long for me to notice the battery drain, particularly when I went out for a walk. In 30 minutes, the battery dropped by 13 per cent while I had my AirPods Pro connected via bluetooth, location enabled and Spotify playing. During that time I also sent some messages via Facebook Messenger and Slack. I went on a similar walk the next day and lost 10 per cent battery in 20 minutes - this time around I had added some light browsing into the mix. That being said, the battery still go me through the whole day. I started using the device at 7:30am and by 11:30pm it was down to 3 per cent. As a moderate to heavy user, this was okay. However, if Australia wasn't in lockdown right now I would probably have run out of battery earlier due to heavier music listening and reading on my morning commute, as well as connecting my Apple watch for gym workouts and taking the phone out after work. If the world was normal right now, I would definitely need to be put the SE on a charger during the day. Apple's iPhone SE: Every Phone Plan In Australia Apple mic-dropped the mobile world last week by unveiling a brand new iPhone SE for just $749. Not only that, even the most expensive version of the mid-range phone still comes in at under $1000. The phone is on sale today, and every major Aussie telco is on board with this little beauty. Because opening 500 tabs to compare phone plans sucks, we have rounded up all of them for you. You're welcome. Read more But despite my battery complaints, it's important to take my own experience and background into account. I review phones for a living and use an iPhone 11 Pro Max regularly. And in recent weeks, I've been playing around with the Samsung S20 Ultra and Huawei P40. These are flagship phones with huge batteries. My prediction is that people most likely to buy an iPhone SE will be upgrading from an older Apple device, such as an iPhone 6, 7 or 8. Alternatively, they're low to moderate phone users who simply want a cheaper device without having to make a lot of compromises. If these scenarios sound like you, the battery life on the iPhone SE will be just fine. You'll probably find that it's on par with the iPhone 8 and still larger than anything older than that – especially when you take battery degradation into account. Plus, the iPhone SE charges incredibly quickly thanks to 30W fast-charge capabilities, combined with the smaller battery. I even found that the wireless charging on it was quite speedy. If you want a more robust battery, you should consider upgrading to an iPhone 11 or 11 Pro instead. But if you don't mind something a bit smaller, the iPhone SE could be likely be perfect for you. iPhone SE Bezel While this isn't a problem for me, this will probably bug some people. So let's talk about it. The 4.7-inch display has quite a thick bezel at the top and bottom of the device to house the home button and front-facing camera. This makes sense because it would cost a lot more to include an in-screen fingerprint reader and camera. However, some folks may not like how this throwback inclusion eats into the screen real estate, especially if they enjoy streaming content on their phones. While it's not my favourite feature, the bezels really don't bother me that much and after a few days of use I don't really miss Face Unlock. I also found watching Netflix and Quibi on the SE great. The smaller screen didn't bother me and the brightness and quality of the display was lovely. However, if you're a fan of having as much screen as possible, it's probably worth considering one of the Phone 11 models instead. Is the iPhone SE Worth It? Image: Tegan Jones/Gizmodo Australia I've only had the iPhone SE in my hot little hands for a couple of days, so I'll hold my hard stance recommendations until my full review. That being said, this is a great device for the price point – even if you are still paying a premium because it's Apple. While it doesn't have all the bells and whistles of the more expensive iPhones, there's more than enough of them to be perfect for some people. At the same time, it still offers some flagship features you usually have to pay more for, so it's future proofed for a few years. Qi wireless charging, eSIM functionality and water resistance are all fantastic inclusions – but the real game changer here is the A13 bionic chip. Being able to get the best phone processor on the market in a sub-$1000 phone is a real power move by Apple, and one that will probably pay off for them. The iPhone SE is as modern as it is thoughtful. It provides an option for people on a tighter budget or who don't want to stretch their fingers across the mammoth phone screens that have become the norm over the last few years. Trending Stories Right Now apple au feature iphone-se Apple iPhone SE: Australian First Look Review Tegan Jones 24 Apr 2020 2:25 PM Last year, Google turned the mid-range phone market on its head by introducing the ludicrously-priced and well-specced Pixel 3a. A few other brands have followed suit since then, but none have been quite as exciting as the new iPhone SE. Now it truly seems like flagship inclusions at lower price points are here to stay - and it's about damn time. The trend of $1,500 - $2,000 becoming the norm for new phones over the last few years has been bad for buyers. A new middle ground has been long overdue and we welcome it. But is the resurrected iPhone SE actually a good phone to buy in 2020? books chang-chen charlotte-rampling denis-villeneuve dune frank-herbert io9 jason-momoa javier-bardem josh-brolin oscar-isaac rebecca-ferguson stellan-skarsgard timothee-chalamet warner-bros zendaya A Guide To Dune's Gargantuan Cast Of Characters Beth Elderkin 24 Apr 2020 1:02 PM This could be the biggest movie event of 2020—and we mean that literally. There are so many characters in Dune that it’s hard to keep them straight. We’ve got a handy guide to the biggest characters in Denis Villeneuve’s adaptation (with as few spoilers as possible) and who’s playing them, as well as a few others we hope to see in the sequel. Want Gizmodo's email newsletter? Enter your email address Follow us, subscribe and get in touch! Latest Deals Deals: $300 Off Samsung Galaxy S20 5G And S20+ 5G Phones The Fastest NBN Providers According To Netflix Dayum, Telstra Just Doubled The Data Of Its Cheapest Plan Tell Us How You're Coping With The Coronavirus Epidemic And You Could Win A $500 Uber Eats Voucher Trending Articles 1Apple iPhone SE: Australian First Look ReviewApple iPhone SE: Australian First Look Review 231 Little-Known Settings On Your Phone And Laptop You Should Know About31 Little-Known Settings On Your Phone And Laptop You Should Know About 3A Guide To Dune's Gargantuan Cast Of CharactersA Guide To Dune's Gargantuan Cast Of Characters Here’s What You Oughta Know About Grabbing Cash Out Of Your Super During The PandemicI Looked Up Foot Fetish Porn For A Lol But Now It’s The Only Thing That Gets Me OffThese Embarrassing As Hell Work Stories’ll Make You Clench For EternityI Genuinely Fear For My Social Skills Once Iso Is Over & We Have To, You Know, Interact Battlefield V Set For Final Content Drop As Development Shifts To SequelIndie Developers Are Keeping The PlayStation Vita AliveRevenge Of The Cartels, Mayhem 2.0, Loot The Universe Now Available In Borderlands 3All The Bugs And Fish Leaving Animal Crossing: New Horizons In April Send Packages To Nearby Friends Using Uber ConnectThe Best Recipes For ANZAC Day BiscuitsReminder: No ANZAC Day Long Weekend For Most Of Us This YearWhat Is Dalgona Coffee? The 26 best players still available after the first round of NFL draftGreen Bay Packers pull off one of the biggest surprises of the draft, trading up to draft quarterback Jordan Love as a possible successor to Aaron RodgersFitness Australia says gyms should be reopened if they follow strict guidelines – but an expert says the conditions aren't right 'just yet'Singapore's richest man is getting $1 billion richer each month from selling ventilators © 2007-2020 Pedestrian GroupAboutAdvertiseContactTerms of UseGizmodo International Sign up for Gizmodo Australia's breaking news alerts and get the best stories straight away AllowClose SKIP NAVIGATION BREAKING Oil rallies more than 40% in two days as it comes back from record lows logo SIGN IN PRO WATCHLIST MAKE IT SELECT USA INTL logo MARKETS BUSINESS INVESTING TECH POLITICS CNBC TV SEARCH QUOTES HEALTH AND SCIENCE Gilead says draft of coronavirus treatment results contain ‘inappropriate characterization’ and are ‘inconclusive’ PUBLISHED THU, APR 23 20201:22 PM EDTUPDATED MOMENTS AGO Berkeley Lovelace Jr. @BERKELEYJR KEY POINTS Gilead shares fell after a report, citing a draft document, said antiviral drug remdesivir did not improve Covid-19 patients’ condition or reduce the virus’ presence in the bloodstream in a phase 3 clinical trial. Gilead said the document contained “inappropriate characterizations” and that the study’s findings were “inconclusive.” AP: Gilead Sciences 150709 In this July 9, 2015, file photo, a man walks outside the headquarters of Gilead Sciences in Foster City, Calif. Eric Risberg | AP Gilead Sciences said that a draft document showing disappointing results from a closely watched clinical trial of the company’s treatment for the coronavirus contained “inappropriate characterizations” and that the study’s findings were “inconclusive.” Shares of the biotech firm fell 4% in intraday trading Thursday after the Financial Times reported that antiviral drug remdesivir did not improve Covid-19 patients’ conditions or reduce the virus’ presence in the bloodstream in a clinical trial in China. The report, citing a draft document that was accidentally published by the World Health Organization and has since been removed, also said the drug showed significant side effects, and some patients were taken off of it. “We regret that the WHO prematurely posted information regarding the study, which has since been removed. The investigators in this study did not provide permission for publication of results,” a Gilead spokesperson said in a statement to CNBC. “Furthermore, we believe the post included inappropriate characterizations of the study. Importantly, because this study was terminated early due to low enrollment, it was underpowered to enable statistically meaningful conclusions,” according to Gilead. “As such, the study results are inconclusive, though trends in the data suggest a potential benefit for remdesivir, particularly among patients treated early in disease.” VIDEO00:30 Gilead halted after report Remdesivir flopped in coronavirus trial There are no proven therapies to treat Covid-19, which has infected more than 2.6 million worldwide and killed at least 183,820 as of Thursday, according to data compiled by Johns Hopkins University. U.S. health officials say producing a vaccine to prevent Covid-19 will take at least 12 to 18 months, making finding an effective drug treatment soon even more crucial. There a number of ongoing studies testing Gilead’s remdesivir to see if it’s effective in stopping the coronavirus from replicating. Last week, Gilead surged after details leaked of one of its clinical trials, showing what appeared to be promising results in treating the disease. The University of Chicago found that patients with Covid-19 had “rapid recoveries in fever and respiratory symptoms” and were discharged in less than a week, according to STAT News. The recent swings in Gilead shares over the past week show just how difficult it is to bet on developments for treatments for the coronavirus. Mike Bailey, director of research at FBB Capital Partners and a former health-care analyst at Stifel, told CNBC last week that retail investors are “hungry” for good news on the virus. Those investors could be taking that and channeling it into buying shares, he said. “You could argue [Gilead] buyers are hungry for good news while Moderna buyers are starving for it,” said Mike Bailey, referring to Moderna’s coronavirus vaccine currently in human trials. Remdesivir has shown some promise in treating SARS and MERS, which are also caused by coronaviruses. Some health authorities in the U.S., China and other parts of the world have also been using remdesivir, which was tested as a possible treatment for the Ebola outbreak, in hopes that the drug can reduce the duration of Covid-19 in patients. Results from a Gilead clinical trial involving patients with severe cases of the virus are expected later this month, while data on a trial testing patients with moderate symptoms is expected in May. Infectious disease experts and analysts caution the severe study is “single-arm,” meaning it will not evaluate the drug against a group of patients who didn’t receive the drug. TRENDING NOW Jamie Black-Lewis received loans from the Paycheck Protection Program for her two spas, Oasis Medspa & Salon and Amai Day Spa, in Washington state. Many of her 35 employees think they will make more money collecting unemployment benefits than from their regular paychecks. She got a forgivable Paycheck Protection Program loan. Her employees hate her for it. Remember what this felt like? People enjoy the warm spring weather at Hornstull in Stockholm on April 21, 2020, during the new coronavirus COVID-19 pandemic. Sweden resisted a lockdown, and its capital Stockholm is expected to reach ‘herd immunity’ in weeks New York Governor Andrew Cuomo (D) speaks during a press Conference at the State Capitol. Cuomo rips McConnell’s ‘really dumb’ suggestion to let states declare bankruptcy over coronavirus Treasury Secretary Steven Mnuchin speaks during the daily briefing on the novel coronavirus, COVID-19, in the Brady Briefing Room at the White House on April 2, 2020, in Washington, DC. US issues new guidance for small business loans, pressures public companies to return funds New York Governor Andrew Cuomo (D) speaking at a press Conference at the State Capitol reporting on the latest development of the Covid-19 Coronavirus situation. New York antibody study estimates 13.9% of residents have had the coronavirus, Gov. Cuomo says by TaboolaSponsored LinksFROM THE WEB Si tu aimes jouer, ce jeu de construction de ville est pour toi. Pas d’installation. 14 215 876 y jouent ! Forge Of Empires - Jeu en ligne gratuit Programme Photovoltaique - Originale Gratuit & Sans Engagement logo Subscribe to CNBC PRO Licensing & Reprints CNBC Councils Supply Chain Values Advertise With Us Join the CNBC Panel Digital Products News Releases Closed Captioning Corrections About CNBC Internships Site Map AdChoices Careers Help Contact News Tips Got a confidential news tip? We want to hear from you. GET IN TOUCH CNBC Newsletters Sign up for free newsletters and get more CNBC delivered to your inbox SIGN UP NOW Get this delivered to your inbox, and more info about our products and services. Privacy Policy|Do Not Sell My Personal Information|Terms of Service © 2020 CNBC LLC. All Rights Reserved. A Division of NBCUniversal Data is a real-time snapshot *Data is delayed at least 15 minutes. Global Business and Financial News, Stock Quotes, and Market Data and Analysis. Market Data Terms of Use and Disclaimers Data also provided by Reuters We and our partners use cookies on this site to improve our service, perform analytics, personalize advertising, measure advertising performance, and remember website preferences. By using the site, you consent to these cookies. For more information on cookies including how to manage your consent visit our cookie policy. CONTINUE Search by symbol, author, keyword... Sign in Marketplace Subscribe Premium My Portfolio Authors Top Stocks Latest News Markets Stock Ideas Dividends ETFs Investing Strategy Podcasts Help & Support Healthcare | On the Move BioSig up 10% on encouraging data on COVID-19 antiviral Apr. 23, 2020 9:49 AM ET|About: BioSig Technologies, Inc. (BSGM)|By: Douglas W. House, SA News Editor BioSig Technologies (BSGM +10%) is up out the gate on the heels of results from laboratory studies comparing the antiviral activity of subsidiary ViralClear's merimepodib to Gilead Sciences' (GILD +2.2%) remdesivir. Cell cultures were pretreated with two concentrations of either merimepodib or remdesivir for four hours before SARS-CoV-2 virus was added. At hour 16, both concentrations of the former and the higher concentration of the latter significantly reduced viral production. At hour 24, both concentrations of both drugs significantly reduced viral production. Additional studies are underway. ViralClear intends to launch clinical trials in COVID-19 next quarter (assuming FDA sign-off). Merimepodib is a broad-spectrum antiviral that Vertex Pharmaceuticals (VRTX +1.5%) was originally developing for hepatitis C and psoriasis. See all stocks on the move » 413 people get BSGM breaking news and analysis by email alert Get email alerts on BSGM Recommended for you: DoctoRx Why Gilead's COVID Drug May Be The Magic Bullet We Need DoctoRx • Apr. 19, 2020 11:06 PM ET WG Investment Research Bank Of America: This Time Will Be Different, Seriously WG Investment Research • Apr. 23, 2020 8:10 PM ET Wall Street Breakfast Wall Street Breakfast: First Oil Major To Cut Dividend Wall Street Breakfast • Apr. 23, 2020 1:00 PM ET Robert & Sam Kovacs Johnson & Johnson: I Don't Want To Say I Told You So Robert & Sam Kovacs • Apr. 22, 2020 7:38 PM ET Eric Parnell, CFA The Bear Is On The Prowl Eric Parnell, CFA • Apr. 23, 2020 4:34 PM ET Comments 9 • Sort by Add Your Comment User 50681444 Comments27 | + Follow He is a very smart man , it would be smart fro Trump to own it. It was just proved to work better than the biggest hopeful Remdesivir in lab test! And , this is the kicker - This drug is in pill form which means that the patient can take it at home!!! This stock is going to blow up !!! Buy it while you can! 23 Apr 2020, 01:15 PMReply0Like Rudester Comments5178 | + Follow Anybody knows if Trump owns stock in this one, like he does in the largest maker of hydroxychloroquine? 23 Apr 2020, 11:32 AMReply1Like alphaseek2018 Comments1514 | + Follow Yes he has a $99 holdings in hydroxychloroquine maker. Give me a break! 23 Apr 2020, 12:55 PMReply1Like 6x7 bigelk Comments74 | + Follow Go INO go 23 Apr 2020, 11:20 AMReply0Like Oil Can Comments2739 | + Follow Good news. We need to move forward to clinical trials every drug that has potential against COVID-19. This will not be a one-and-done game; we need to have multiple candidates under evaluation until a clear winner - or winners - emerge. As I understand it, once we have a viable therapeutic, there is the possibility of accelerating vaccine trials. 23 Apr 2020, 10:46 AMReply0Like APB Comments881 | + Follow So this new treatment might be ready to go in 3 or 4 years? If 20% of the population does in fact already have antibodies for COVID 19 then it will probably be obsolete before it reaches phase 2 trial? 23 Apr 2020, 10:43 AMReply0Like Matt-Man Comments2983 | + Follow Getting safety profile would take year alone, maybe 7-10year if lucky. Also HydroChloroquine had great in-vintro results 23 Apr 2020, 10:58 AMReply1Like Todd Kenyon, CFA Comments326 | + Follow This is in a culture - so far from being approved. I could dump Clorox in that culture and it would kill the virus too. The hcq jury is still out as the negative results were just one crappy anecdotal study with many issues. As were the positive ones. We don’t know yet bottom line. 23 Apr 2020, 10:18 AMReply9Like LilKleine Comments18 | + Follow Some good news after the disappointing results from the hydroxychloroquine study 23 Apr 2020, 10:02 AMReply0Like RSS Feeds|Advertise with Us|Sitemap|About Us|Feedback|Careers|Contact Us Terms of Use|Privacy|Market Data Disclaimer|© 2020 Seeking Alpha GlobeNewswire Intrado Logo Search REGISTER SIGN IN ENGLISH FRANÇAIS CONTACT US GLOBAL DISTRIBUTION NEWSWIRE SERVICES REGULATORY FILINGS MEDIA PARTNERS Bio-Sig-Logo-horiz.jpg ViralClear Publishes Comparative In Vitro Data on Merimepodib and Remdesivir Activity Against the COVID-19 Novel Coronavirus in F1000 Research Email Print Friendly Share April 23, 2020 09:15 ET | Source: BioSig Technologies, Inc. Westport, CT, April 23, 2020 (GLOBE NEWSWIRE) -- Merimepodib is shown to decrease viral production of COVID-19 coronavirus more than remdesivir at clinically meaningful drug concentrations in pre-clinical testing. Article highlights recent work done in laboratory studies of COVID-19 with merimepodib at the Galveston National Laboratory at The University of Texas Medical Branch BioSig Technologies, Inc. (Nasdaq: BSGM) today announced that an article titled, “The IMPDH inhibitor merimepodib has similar antiviral activity against SARS-CoV-2 replication in vitro to the adenosine analogue remdesivir” was accepted by F1000 Research, an online peer-reviewed life sciences journal publishing program in biology and medicine. This manuscript is authored by Natalya Bukreyeva, Rachel A. Sattler, Emily K. Mantlo, John T. Manning, Cheng Huang and Slobodan Paessler of the UTMB Galveston National Laboratory and Dr. Jerome Zeldis of ViralClear Pharmaceuticals, Inc. (“ViralClear”) as a corresponding author. The article highlights emerging pre-clinical data generated under contract with Galveston National Laboratory at The University of Texas Medical Branch. The work was started with Trek Therapeutics and after merimepodib was acquired by ViralClear has been continued by ViralClear. “The concentrations of merimepodib used in the cell culture studies described in this article are achievable in humans by our oral solution formulation,” said Dr. Zeldis, Executive Chair and Founder of ViralClear Pharmaceuticals, Inc. “We are now exploring whether remdesivir and merimepodib are synergistic in this in vitro model. We look forward to starting our first clinical trial in COVID-19 patients upon receiving FDA clearance to commence with the proposed phase 2 trial.” Vero cells in tissue culture were pre-treated with two concentrations (2.5 and 5 µM) of either merimepodib or remdesivir for 4 hours before the SARS-CoV-2 coronavirus was added. The amount of virus released to the media was measured at baseline and 16 hours and 24 hours after infection. At 16 hours, a significant reduction in viral production was observed for both concentrations of merimepodib (1.9 log decrease in titer, p = 0.003 and 2.1 log decrease in titer, p = 0.001) but only at the higher concentration of remdesivir (1 log decrease in titer, p = 0.103 and 2.1-log decrease in titer, p = 0.001). At 24 hours both concentrations of both drugs significantly reduced viral production; however, 2.5 µM remdesivir reduced viral titer by 1.5 logs (p = 0.002) as compared to a decrease of 3.9 logs for 5 µM remdesivir (p < 0.001), whereas 2.5 and 2.7 log reductions (p = 0.001 and p < 0.001, respectively) were observed for the 2.5 and 5 µM concentrations of merimepodib. Merimepodib, a broad-spectrum anti-viral candidate, demonstrated strong activity against COVID-19 in cell cultures in laboratory testing and additional antiviral studies are underway. Merimepodib was previously in development as a treatment for chronic hepatitis C and psoriasis by Vertex Pharmaceuticals Incorporated (Vertex), with a 12 clinical trials conducted (including 315 chronic hepatitis C patients, 24 psoriasis patients, and 98 healthy volunteers) and an extensive preclinical safety package completed . ViralClear intends to pursue development of this agent for the treatment of COVID-19 through FDA-approved clinical trials in Q2 2020. About BioSig Technologies BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals (www.biosig.com). The Company’s first product, PURE EP(tm) System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory. About ViralClear BioSig’s subsidiary ViralClear Pharmaceuticals, Inc., is seeking to develop a novel pharmaceutical to treat advanced COVID-19. Merimepodib is a broad-spectrum anti-viral agent that has demonstrated strong activity against the COVID-19 virus in cell cultures in laboratory testing. ViralClear plans to initiate a multi-center, phase 2, randomized, double-blind, placebo-controlled study of the efficacy and safety of merimepodib administered orally every eight hours for 10 days in adult patients with advanced COVID-19 upon FDA clearance to proceed. Merimepodib has been studied in twelve clinical trials prior to this study, including five trials in patients with hepatitis C (one phase 1b, one phase 2, two phase 2a, and one phase 2b), one trial in patients with psoriasis (phase 2), and six trials in healthy volunteers (all phase 1). Forward-looking Statements This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward- looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the geographic, social and economic impact of COVID-19 on our ability to conduct our business and raise capital in the future when needed, (ii) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (iii) difficulties in obtaining financing on commercially reasonable terms; (iv) changes in the size and nature of our competition; (v) loss of one or more key executives or scientists; and (vi) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise. Andrew Ballou BioSig Technologies, Inc. Vice President, Investor Relations 54 Wilton Road, 2nd floor Westport, CT 06880 aballou@biosigtech.com 203-409-5444, x133 Related Articles More articles issued by BioSig Technologies, Inc. More articles related to: Company Announcement Profile BioSig Technologies, Inc. Subscribe via RSS Subscribe via ATOM Javascript Westport, Connecticut, UNITED STATES Contact Data Andrew Ballou BioSig Technologies, Inc. Vice President, Investor Relations 54 Wilton Road, 2nd floor Westport, CT 06880 aballou@biosigtech.com 203-409-5444, x133 Contact Biosig Technologies (BSGM) Intraday 3 Month 6 Month 1 Year Last: $7.50 Change: +0.30 % Change: +4.17% Volume: 1M Open: $7.14 Previous Close: $7.20 Low: $7.14 High: $8.32 Market Cap: 0 Shares Outs.: 0 EPS: 0.00 P/E Ratio: - Dividend: N/A Yield: N/A 52 Week Low: $2.36 52 Week High: $9.97 Quote delayed at least 20 mins. Media Files Bio-Sig-Logo-horiz.jpg Logo Download Options Bio-Sig-Logo-horiz.jpg LOGO URL | Copy the link below http://www.globenewswire.com/attachment-download-view/2021020/564767/4/1/0/564767.jpg Tags HEALTHMEDICALelectrophysiologystocknasdaqdeviceinvestorarrhythmiaAfibVTheartEPscienceablationbioelectronic medicine Related Links https://www.biosig.com/ Newswire Distribution Network & Management Home Newsroom RSS Feeds Legal About Us GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public. © 2020 GlobeNewswire, Inc. All Rights Reserved. Trinidad and Tobago Newsday News Latest Sports Sections N Touch NEWS Hypertension patients, diabetics at high risk for covid 19 RYAN HAMILTON-DAVIS 4 HRS AGO File photo - File photo - The elderly are not the only people especially at risk for contracting covid19. People with hypertension, diabetes and kidney disease are also at high risk. So said Dr Neil Bhagwandass, nephrologist at San Fernando Hospital, at the Wednesday's covid19 update at the Ministry of Health headquarters on Park Street in Port of Spain. He listed the categories of people especially susceptible to the disease, which also included people who have suffered strokes or who have had lung diseases. Trendingview all 1 Designer defends $75, $100 cloth masks after backlash NARISSA FRASER 2 SORT foils alleged murder plot SHANE SUPERVILLE 3 Two held in Barrackpore after chase, 2 on the run LAUREL V WILLIAMS 4 Deyalsingh: Suspected case at step-down facility SHANE SUPERVILLE 5 Judge orders couple’s release JADA LOUTOO 6 ‘Stay at home’ challenged JADA LOUTOO 7 Brother, sister gunned down at home LAUREL V WILLIAMS Comments "Hypertension patients, diabetics at high risk for covid 19" More in this section NEWS Msgr Pereira: Spread Muslim fast to other religions YVONNE WEBB NEWS Corporations get $1m each to fight covid19 YVONNE WEBB NEWS CoP calls on public: Give info to reduce murders SHANE SUPERVILLE NEWS Attorney: People may sue over roadblocks SEAN DOUGLAS Trinidad and Tobago Newsday© 2020 Trinidad and Tobago Newsday. N Touch About Us Staff Classifieds Advertise Privacy Policy Contact Us Share to Facebook Share to WhatsApp Share to Twitter Share to Email Share to Print More AddThis Share options Skip to main content Thursday 23 April, 2020 Loop Market Trinidad And Tobago Home Search T&T News World News COVID-19 Carnival Viral Entertainment Lifestyle Business Sport BREAKING NEWS | Over 300,000 with hypertension at higher COVID-19 risk, says Minister ALINA DOODNATH CREATED : 23 APRIL 2020COVID-19[iStock.com/FatCamera] [iStock.com/FatCamera] Thousands of Trinidadians with diabetes and hypertension are at a higher risk due to the novel coronavirus (COVID-19), which if it spreads, ‘could be a disaster’, according to the Health Ministry. Speaking at Thursday’s media briefing to update the public on COVID-19 measures, Health Minister Terrence Deyalsingh said 341,000 people were diagnosed with hypertension, according to Ministry statistics – 23.6 percent of the population. He added that 266,000 (20.5 percent) of the population suffer from diabetes, saying that the figure is probably an underestimation as many people may not be aware they have diabetes. Dr Neal Bhagwandass, Nephrologist and Acting Head of Department, Medicine, at the San Fernando General Hospital, said it is critical that dialysis patients do not contract or spread the virus when receiving treatment. He said there are approximately 1,400 patients receiving hemodialysis treatments through the public health care system. "A typical dialysis would have 20-30 patients dialysing at one time. Our nephrologists have instituted policies so that patients are not allowed to congregate. Patients should be kept at least six feet apart and as soon as the dialysis procedure is finished they are to leave the environment." He said dialysis patients are screened on entering and are asked about any flu-like systems. "If we have to swab, swab them because this is a very high-risk population...we do not want COVID-19 to spread among our dialysis population, that could be a disaster." Dr Bhagwandass said those patients can experience kidney failure if they were to contract the virus. Dr Bhagwandass said diabetic patients should not work if they are feeling unwell. “Any stress on a diabetic patient would predispose you to your diabetes going out of control. These people should practice ‘sick day’ guidelines. If you become unwell, you develop…flu-like symptoms, your blood sugar would spike. “The rule is not to stop your diabetic medicine…get in contact with your health professionals for further advice.” Also concerning is the fact that young people who tested positive for the virus in other countries have been seen to develop abnormal clotting due to the virus. “Even young people who do not manifest these (diseases), are being diagnosed with strokes, cardiovascular accidents, because of increased clotting that occurs when one develops a COVID-19 infection.” People with the following conditions are at higher risk of severe COVID-19 complications: - Asthmatics - Chronic lung disease - Diabetes - Serious heart conditions - Chronic kidney disease/Dialysis - Severe obesity - Elderly (65 years and older) - Carehome residents - Immunocompromised - Liver disease Deyalsingh said the Ministry has implemented several measures to reduce the prevalence of non-communicable diseases including the banning of soft drinks at public schools, which he said has reduced soft drink consumption among children by 25 percent. He added that over the past year there was a drop in visits to the Accident and Emergency departments by 1.5 to two percent for people with hypertension and diabetes. Get the latest local and international news straight to your mobile phone for free: DIALYSIS DIABETES HYPERTENSION MINISTRY HEALTH DR ROSHAN PARASRAM DR NEAL BHAGWANDASS TRINIDAD CORONAVIRUS COVID-19 Related articles Comments Share this article Share to FacebookShare to TwitterShare to LinkedInShare to WhatsAppShare to MessengerShare to EmailShare to TelegramShare to More124 Trending Recent News Loop News Theme SECTIONS T&T NewsWorld NewsCOVID-19CarnivalViralEntertainmentLifestyleBusinessSport LOOP NEWS Privacy PolicyComments PolicyAbout UsContact UsSubmit an Article NEWSLETTER Email COPYRIGHT 2017 BY TREND MEDIA | ALL RIGHTS RESERVED Electropages icon Electropages uses cookies to give you the best experience. I'm fine with thisInformation and Settings Electropages logo Home Insights Product News NPI Channels Search Term Magnifying glass icon Tetherless pulse oximeter can monitor COVID-19 patients at home 23-04-2020 | Nordic | Test & Measurement Nordic Semiconductor is meeting demand for its high-end Bluetooth SoC. This lies at the heart of an industry-leading, battery-powered wireless pulse oximeter, the Radius PPG, that was launched last year by Masimo and is now set to join the front-line battle against COVID-19 as part of that company's SafetyNet solution. As the Radius PPG is created to enable tetherless monitoring, it can be used as part of the SafetyNet platform to remotely manage COVID-19 patients at home and conceivably assist hospitals from being overwhelmed by less severe cases. "We didn't originally develop Radius PPG to combat COVID-19," says Bilal Muhsin, chief operating officer, Masimo. "We first and foremost developed it so it could monitor hospital patients accurately, even when the patient is moving, without the inconvenience of a wired connection to a monitor. But it turns out that in the current COVID-19 crisis this tetherless capability, when paired with a secure, cloud-based telehealth platform accessible from a smartphone for patients and from a web-based dashboard for providers, can provide a valuable way to manage COVID-19 patients who do not require hospitalisation. And continue to check them from their homes, allowing hospital beds to be freed up for those who need it. Masimo SafetyNet uses the same Radius PPG tetherless pulse oximeter designed for use in the hospital to provide a remote patient management solution small enough to be worn comfortably and simple enough to be set-up quickly on the patient's smartphone." "Our hearts go out to the brave front line medical and hospital personnel doing their absolute best to cope with the often overwhelming numbers of COVID-19 patients coming through their doors in COVID-19 hotspots around the world," concludes Geir Langeland, Nordic Semiconductor director of sales and marketing. Nordic's latest multiprotocol SoC is its most advanced ultra low power wireless solution. The SoC supports complex Bluetooth LE and other wireless applications that were previously not possible with a single-chip solution. Nordic logo Facebook icon Twitter icon LinkedIn icon Email icon Print icon Related product news Next generation proximity sensors for GAPS and HAPS 22-04-2020 | Test & Measurement Motion detector aids designers in adding different technologies 21-04-2020 | Test & Measurement New sensor solution for ventilators 20-04-2020 | Test & Measurement Cost-effective MEMS sensors give increased performance and reliability 17-04-2020 | Test & Measurement Information Contact Us About Archive Submit PR Advertise Manage newsletter Subscribe Manage Subscription RSS feeds Our apps Apple icon Android icon Social profiles Facebook icon Twitter icon All news & general enquiries: +44 (0)1202 237137 info@electropages.com Copyright © 2020 Electropages Media Ltd Cookie Policy | Privacy Policy Electropages Media logo